Athira Pharma Reports First Quarter 2023 Financial Results a

Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term... | May 11, 2023

Related Keywords

Washington , United States , Seattle , American , Julie Rathbun , Mark Litton , Athira Pharma , International Conference On Alzheimer , Facebook , American Association Of Neurology , Nasdaq , Securities Exchange , Athira Pharma Inc , Instagram , Linkedin , Development Rd Expenses , Exchange Commission , National Institutes Of Health , Twitter , Clinical Development Pipeline Programs , Drug Administration , Chief Executive Officer , Mini Mental State Exam , Label Extension , National Institute , National Institutes , American Association , Related Neurological Disorders , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Consolidated Statements , Nc Stock Exchange , News , Information , Press Release , Hase , Trial , F , Fosgonimeton , Or , Disease , O , Focus , N , 0 , G , Nose , Pen , Label , Extension , The , Roviding , P , 6 , Months , F Atha Us04746l1044 ,